All In Biotech

Drug Trial Radar · NCT04337879

A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer

A Phase Ib Study to Evaluate the Efficacy and Safety of AL2846 Capsule Combined With Chemotherapy (mFOLFOX6 or FOLFIRI)Versus Placebo Combined With Chemotherapy in Subjects With Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jul 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

56

Planned (sponsor's estimate)

Start

Jul 20, 2020

Primary completion

Dec 31, 2020

Study completion Dec 31, 2020

Sponsor

Sponsor type
Industry
First posted
Apr 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic colorectal cancer.

Conditions

  • Advanced Colorectal Cancer

Interventions

  • AL2846Drug

    AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.

  • Calcium folateDrug

    Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle

  • 5-FUDrug

    5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.

  • OxaliplatinDrug

    Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.

  • IrinotecanDrug

    Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: up to 12 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of China Medical University

    Shengyang, Liaoning, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.